-
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Hypoxia-inducible factors (HIFs) are highly conserved transcription factors that are crucial for adaptation of metazoans…
-
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
As you may have heard that Liquid biopsy has become an attractive tool for a…
-
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Researchers promises that AMG 509 provides a targeted immunotherapy approach to engage a patient’s T…
-
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
A recent first-in-human phase I study shows the safety and preliminary efficacy of nemtabrutinib in…
-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
A recent study shows that First-line serplulimab plus chemotherapy improves PFS and OS and promises…
-
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Researchers indentified interferon-stimulated, Ly6Ehi neutrophils as a blood-borne biomarker of anti-PD1 response in mice at…